Currently, gedatolisib is being evaluated in the phase III VIKTORIA-1 trial combined with fulvestrant with or without the CDK4/6 inhibitor palbociclib in patients with HR-positive, HER2-negative advanced breast cancer who progressed on CDK 4/6 therapy (NCT05501886). Here, ERBB2 is linked to breast cancer.